Clinical trials: CAR-T
Malignant Glioma, Glioblastoma
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with gliomas that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Malignant Glioma, Glioblastoma, Brain Cancer, Gliosarcoma
- Trial name
- NCT01454596
- Testing
- Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL, Aldesleukin, Fludarabine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma
EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma
Please note that enrollment on this study terminated early due to the end of grant funding. Newly diagnosed WHO grade IV malignant glioma subjects who are eligible were enrolled following surgery to remove their brain tumor.
- Trial name
- ExCeL (NCT02664363)
- Testing
- EGFRvIII CAR T cells
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Daniel Landi
Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Nektar Study 18-255-01 was a Phase 2/3, randomized, double blind, placebo-controlled, multicenter study of NKTR-255 versus placebo following CD19-directed CAR-T cell therapy in patients with R/R LBCL.
- Trial name
- NCT05664217
- Testing
- NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Nektar Therapeutics
Relapsed or Refractory Neuroblastoma
A Phase I Trial of Anti-GD2 T-cells (1RG-CART)
The purpose of this first in human study is to determine the safety and feasibility of 1RG-CART therapy in patients with relapsed or refractory neuroblastoma.
- Trial name
- NCT02761915
- Testing
- Leukapheresis, Cyclophosphamide, Fludarabine
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Cancer Research UK